HDAC4 and hepatocellular carcinoma: Previous study has validated that HDAC4 could inhibit the expression of miR-200a and reduce the histone H3 acetylation level at the mir-200a promoter through a Sp1-dependent pathway in hepatocellular carcinoma [30].